413 related articles for article (PubMed ID: 31465598)
1. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells.
Takeda K; Yamada T; Takahashi G; Iwai T; Ueda K; Kuriyama S; Koizumi M; Matsuda A; Shinji S; Ohta R; Yokoyama Y; Hotta M; Hara K; Yoshida H
Cancer Sci; 2019 Nov; 110(11):3497-3509. PubMed ID: 31465598
[TBL] [Abstract][Full Text] [Related]
2. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.
Yamada T; Iwai T; Takahashi G; Kan H; Koizumi M; Matsuda A; Shinji S; Yamagishi A; Yokoyama Y; Tatsuguchi A; Kawagoe T; Kitano S; Nakayama M; Matsumoto S; Uchida E
Cancer Sci; 2016 Jul; 107(7):936-43. PubMed ID: 27116474
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers.
Strauss WM; Carter C; Simmons J; Klem E; Goodman N; Vahidi B; Romero J; Masterman-Smith M; O'Regan R; Gogineni K; Schwartzberg L; Austin LK; Dempsey PW; Cristofanilli M
Oncotarget; 2016 May; 7(18):26724-38. PubMed ID: 27049831
[TBL] [Abstract][Full Text] [Related]
4. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
[TBL] [Abstract][Full Text] [Related]
5. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
El Messaoudi S; Mouliere F; Du Manoir S; Bascoul-Mollevi C; Gillet B; Nouaille M; Fiess C; Crapez E; Bibeau F; Theillet C; Mazard T; Pezet D; Mathonnet M; Ychou M; Thierry AR
Clin Cancer Res; 2016 Jun; 22(12):3067-77. PubMed ID: 26847055
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
[TBL] [Abstract][Full Text] [Related]
7. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
Gale D; Lawson ARJ; Howarth K; Madi M; Durham B; Smalley S; Calaway J; Blais S; Jones G; Clark J; Dimitrov P; Pugh M; Woodhouse S; Epstein M; Fernandez-Gonzalez A; Whale AS; Huggett JF; Foy CA; Jones GM; Raveh-Amit H; Schmitt K; Devonshire A; Green E; Forshew T; Plagnol V; Rosenfeld N
PLoS One; 2018; 13(3):e0194630. PubMed ID: 29547634
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients.
Sefrioui D; Mauger F; Leclere L; Beaussire L; Di Fiore F; Deleuze JF; Sarafan-Vasseur N; Tost J
Clin Chim Acta; 2017 Feb; 465():1-4. PubMed ID: 27940131
[TBL] [Abstract][Full Text] [Related]
10. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
Pasternack H; Fassunke J; Plum PS; Chon SH; Hescheler DA; Gassa A; Merkelbach-Bruse S; Bruns CJ; Perner S; Hallek M; Büttner R; Bollschweiler E; Hölscher AH; Quaas A; Zander T; Weiss J; Alakus H
Sci Rep; 2018 Oct; 8(1):14941. PubMed ID: 30297788
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
[TBL] [Abstract][Full Text] [Related]
12. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
[TBL] [Abstract][Full Text] [Related]
13. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
Cancer Genet; 2017 Dec; 218-219():39-50. PubMed ID: 29153095
[TBL] [Abstract][Full Text] [Related]
14. Combinatory Analysis of Cell-free and Circulating Tumor Cell DNAs Provides More Variants for Cancer Treatment.
Lee SY; Chae DK; An J; Yoo S; Jung S; Chae CH; Bhak J; Kim BC; Cho DH
Anticancer Res; 2019 Dec; 39(12):6595-6602. PubMed ID: 31810925
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
17. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
18. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
19. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
[TBL] [Abstract][Full Text] [Related]
20. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
